Stock analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The firm’s 50 day moving average price is $0.14.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Best Aerospace Stocks Investing
- MarketBeat Week in Review – 6/24 – 6/28
- What is a Bond Market Holiday? How to Invest and Trade
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.